Trametinib



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Malignant Melanoma 55.2%
Prophylaxis 5.7%
Diabetes Mellitus 4.2%
Neoplasm 4.2%
Hypertension 3.3%
Metastatic Malignant Melanoma 3.0%
Pyrexia 3.0%
Thrombosis Prophylaxis 2.7%
Cough 2.4%
Hypercholesterolaemia 2.4%
Facial Nerve Disorder 2.1%
Hypokalaemia 1.8%
Nausea 1.8%
Febrile Neutropenia 1.5%
Iodine Allergy 1.5%
Medical Diet 1.2%
Pain 1.2%
Wheezing 1.2%
Dehydration 0.9%
Headache 0.9%
Pyrexia 54.4%
Vomiting 7.8%
Chorioretinopathy 3.3%
Ejection Fraction Decreased 3.3%
Hepatic Enzyme Increased 3.3%
Sepsis 3.3%
Alanine Aminotransferase Increased 2.2%
Basal Cell Carcinoma 2.2%
Confusional State 2.2%
Hyponatraemia 2.2%
Pneumonia 2.2%
Squamous Cell Carcinoma 2.2%
Urinary Tract Infection 2.2%
Urosepsis 2.2%
Asthenia 1.1%
Cytomegalovirus Infection 1.1%
Death 1.1%
Fatigue 1.1%
Febrile Neutropenia 1.1%
Hepatotoxicity 1.1%
Secondary
Malignant Melanoma 36.0%
Metastatic Malignant Melanoma 36.0%
Prophylaxis 4.6%
Hypertension 3.9%
Pain 3.3%
Epilepsy 2.6%
Pyrexia 1.8%
Diabetes Mellitus 1.3%
Brain Oedema 1.0%
Depression 1.0%
Gastritis Prophylaxis 1.0%
Metastases To Central Nervous System 1.0%
Pancreatitis 1.0%
Thyroid Cancer 1.0%
Back Pain 0.8%
Colorectal Cancer 0.8%
Dehydration 0.8%
Diarrhoea 0.8%
Hypercholesterolaemia 0.8%
Antipsychotic Drug Level Therapeutic 0.5%
Pyrexia 50.0%
Ejection Fraction Decreased 10.0%
Vomiting 6.4%
Squamous Cell Carcinoma 3.6%
Urinary Tract Infection 3.6%
Diarrhoea 2.7%
Squamous Cell Carcinoma Of Skin 2.7%
Thrombocytopenia 2.7%
Alanine Aminotransferase Increased 1.8%
Basal Cell Carcinoma 1.8%
Dehydration 1.8%
Influenza Like Illness 1.8%
Panniculitis 1.8%
Pneumonitis 1.8%
Rhabdomyolysis 1.8%
Sudden Death 1.8%
Abdominal Pain 0.9%
Aspartate Aminotransferase 0.9%
Atrial Fibrillation 0.9%
Cardiac Failure Congestive 0.9%
Concomitant
Colorectal Cancer 75.0%
Metastatic Malignant Melanoma 25.0%
Death 50.0%
Vomiting 50.0%